

OBI Pharma

Innovation in Action

***Investment Summit of
BIO Asia-Taiwan 2025***

Chief Executive Officer

Heidi Wang, Ph.D.

Safe Harbor Statement

This presentation contains certain forward-looking statements.

These forward-looking statements may be identified by words such as “believes,” “expects,” “anticipates,” “projects,” “intends,” “should,” “seeks,” “estimates,” “future,” “or similar expressions or by discussion of, among other things, strategy, goals, plans, or intentions. Various factors may cause actual results to differ materially in the future from those reflected in forward-looking statements contained in this presentation, among others:

1. Pricing and product initiatives of competitors
2. Legislative and regulatory developments and economic conditions
3. Delay or inability in obtaining regulatory approvals or bringing products to market
4. Fluctuations in currency exchange rates and general financial market conditions
5. Uncertainties in the discovery, development, or marketing of new products or new uses of existing products, including without limitation negative results of clinical trials or research projects, unexpected side effects of pipeline or marketed products
6. Increased government pricing pressures
7. Interruptions in production
8. Loss of or inability to obtain adequate protection for intellectual property rights
9. Litigation
10. Loss of key executives or other employees
11. Adverse publicity and news coverage

OBI Pharma cautions that this foregoing list of factors is not exhaustive. There may also be other risks that management is unable to predict at this time that may cause actual results to differ materially from those in forward-looking statements. **You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date on which they are made. OBI undertakes no obligation to update publicly or revise any forward-looking statements.**

Any statements regarding earnings growth is not a profit forecast and should not be interpreted to mean that OBI’s earnings or earnings per share for this year or any subsequent period will necessarily match or exceed published earnings or earnings per share forecasts of OBI Pharma, Inc.



Taipei
TAIWAN



Melbourne
AUSTRALIA



San Diego
USA



www.obipharma.com

Company Overview



- Established in 2002
- Listed in 2013 (4174.TWO)



- Headquartered in Taipei, Taiwan



- Focus on “**first-in-class**” and “**best-in-class**” ADCs



- Talents in Asia and the U.S.
- >80% with advanced degrees*

Experienced Leaders in Drug Development

Executive Team



Heidi Wang, PhD
Chief Executive Officer



Ya-Chi Chen, PharmD
Chief Scientific Officer



GILEAD



Kevin Poulos
Chief Business Officer



RHÔNE-POULENC

Wyeth



SmithKline Beecham



PTIMER



Dong Xu, PhD
Chief Medical Officer



Bristol Myers
Squibb™



Colin Kao, CPA
Chief Operating Officer



Deloitte.



COMPAL

Precision Medicine: ADCs Deliver Drugs Selectively to Cancer Cells


7+ Years of ADC Experience



VISION

**Right Patient
Right Drug
Right Time**

Obrion Engine™













**ADC recognizes
the target and
enters the cell**

**Payload is released and
cancer cell is killed**

Broad Oncology Pipeline with a Focus on ADC

Modality	Program	Indication	Preclinical	Ph 1	Ph 2	Ph 3	Next Dev. Milestone
ADC  	OBI-992 <i>(TROP2 ADC via Cys conjugation)</i>	Advanced Solid Tumors					Ph1 Readout
	OBI-902 <i>(TROP2 ADC via GlycOBI®)</i>						Ph 1 First Patient In
	OBI-904 <i>(Nectin-4 ADC via GlycOBI®)</i>						IND
	OBI-201 <i>(TROP2x HER2 BsADC via GlycOBI®)</i>	Undisclosed					IND
	Bispecific/ Dual Payload ADC <i>(cMETx HER3 via GlycOBI®)</i>						IND
Prodrug	OBI-3424 <i>(AKR1C3 targeted prodrug)</i>	Liver (HCC) [†] & T-ALL [‡]					Ph 2 Readout


GlycOBI® is a registered trademark of OBI Pharma Inc.

[†] Clinical study conducted by Asentawits (China)


[‡] Clinical study conducted by NIH-SWOG (US)

Glyc **OBI** DUO™ Exhibits Promising Antitumor Activities

Innovation Leads to a New Era of Precision Therapies



Colorectal Cancer CDX




Emrelis™ is a c-Met–targeting ADC carrying an MMAE payload, approved by U.S. FDA May 14, 2025 for the treatment of adult patients with EGFR wild-type, non-squamous non-small cell lung cancer (NSCLC) with high c-Met protein overexpression.

All ADCs were administered as a single dose of **8 mg/kg**, or at an equivalent molar dose, respectively.

Multi-platform Next-generation ADC Technologies

ADCs: the ultimate **designer drugs** to bring **precision** medicine to patients





ASK: Investment Welcome!

Innovative Products and Enabling Technologies



OBI Pipeline Assets Out-License

License Agreement

OBI-992, OBI 902 – Novel TROP2 ADCs

OBI-904 – Novel Nectin-4 ADCs

Bispecific, Single/ Dual-Payload ADCs – TROP2 x HER2, c-MET x HER3

Enabling Technologies Out-License (product candidates)



GlycOBI®

EndoSymeOBI®

HYPrOBI™

GlycOBI DUO™

ThiOBI®

License Agreement

Research Collaboration

Investment Welcome!

Innovation in Action



www.obipharma.com



InvestorRelations@obipharma.com



Our Global Partners

GlyTech, Inc.

TegMine
THERAPEUTICS



Other Potential Collaborations

